EIT-RAWMATERIALS
7.9.2022 09:31:40 CEST | Business Wire | Press release
A leading innovator in science has urged European universities and higher education institutions to revolutionise their innovation activities to effectively tackle climate change. Dr. Riam Kanso, founder and CEO of Conception X, will be the keynote speaker at the INNOVEIT Stockholm: Innovation in Higher Education on 15 September. The event is coordinated and led by EIT RawMaterials, the world’s largest consortium on raw materials, funded by the European Institute of Innovation and Technology (EIT), a body of the European Union.
The registration for in-person or virtual attendance at INNOVEIT Stockholm is now open.
Reaching net-zero carbon emissions by 2050 means new innovations in technology and energy are urgently needed. These innovations will largely stem from universities and higher education institutions. The EIT Higher Education Institutions Initiative (EIT HEI) funds and supports higher education institutions in growing their research and development faculties and boosting entrepreneurship activities and synergies with industry players, many with the aim of accelerating deep tech and energy innovations coming to market (start-ups and spin-offs).
The EIT HEI Initiative is titled ‘Innovation Capacity Building for Higher Education’ and is a unique model that brings together industry/businesses with researchers and higher education. The initiative is a key objective for the EIT as part of the EIT’s new seven-year strategy for 2021-2027. The programme supports higher education institutions with expertise and coaching, access to the EIT innovation ecosystem, and funding to boost the capacity for innovation and entrepreneurship activities at European higher education institutions.
Dr. Kanso: Urgent Progress Needed for Innovation in Higher Education
Dr. Kanso’s company, Conception X, has a complementary mission to the EIT HEI Initiative. Conception X is an independent, non-profit that works closely with more than 30 universities across the UK to discover and train aspiring PhD founders from leading research labs, helping them become eligible for innovation grants, awards, and venture capital funding. Through a nine-month deep-tech venture programme, PhD students explore ways to commercialise their research while still at university – much like the EIT-Labelled Masters and PhD programmes.
Dr. Kanso says new models like this are needed to unleash Europe’s potential as a hotspot for meaningful innovation, especially with the continent’s 2050 deadline to reach net-zero emissions fast approaching.
Dr. Kanso said: “Universities and higher education institutions are built to spread knowledge that improves the world. Yet, the current system of spreading this knowledge by publishing papers can sometimes hinder progress – by the time a paper is published, the research could be three years old. We need to create models where research and innovation come together to reinforce and advance each other.”
EIT RawMaterials CEO Bernd Schäfer stressed: “Europe is at an epochal turning point, where the ambitious goals of the European Green Deal are placing more extraordinary demands on higher education than ever before. Our EIT HEI Initiative was established for this reason, to empower higher education institutions to become engines of innovation and foster sustainable growth and jobs. The initiative brings Europe’s education, research, and industry leaders together to work on strengthened innovation in higher education with the aim of solving some of the world’s biggest problems - like climate change.”
Speaking about the EIT HEI Initiative, Dr. Kanso said: “We’re working to promote knowledge and innovation and help great people excel. The more allies we have and the more connected we are, the easier it will be to achieve that. Network initiatives like the EIT HEI are crucial.’’
INNOVEIT: Stockholm - Focus on Innovation in Higher Education
This hybrid event will highlight the ongoing work of the EIT’s HEI Initiative. Discussions will focus on how the EIT HEI Initiative will connect with deep tech innovations and talents and EIT-Labelled education programmes for enhanced innovation capacity building.
All active projects selected for both the EIT HEI’s Cohort 1 (launched in July 2021) and Cohort 2 (launched in July 2022) will be present at the event. There are 23 active Cohort 1 and 26 active Cohort 2 projects in the HEI Initiative network. Cohort 1 projects will share the good practices and methodologies they have learned so far for increasing innovation capacity in European higher education institutions.
Dr. Tamer Abu-Alam is the Project Coordinator of one of EIT HEI Initiative’s funded Cohort 1 projects, CloudEARTHi, and an academic at UiT, the Artic University of Norway.
Dr. Abu-Alam says initiatives like the EIT HEI Initiative, and this event, are crucial because Europe can only be decarbonised if industry, research, and higher education work closely together.
‘’Without this coming together of stakeholders we cannot achieve a solution to the climate crisis. We are all working on the same problem - but from different perspectives. This is why the EIT HEI and the Stockholm event are so important - because everyone is brought together, everyone presents their point of view, and based on this we can innovate and work together to address this challenge.”
The CloudEARTHi project guides students on how to develop their business plan in line with the European Green Deal, and how to use big data to address gaps in their business model. Within just two months, one student has already started his own business to recycle computer components – an activity that will help to provide the EU with specific raw materials necessary for the green transition.
Dr. Tamer Abu-Alam will also take part in the panel discussion ‘EIT HEI Initiative: Innovation capacity building good practices.’
The event is an integral part of the INNOVEIT WEEKS, a series of events showcasing how EIT, Europe’s largest innovation ecosystem, offers unique opportunities to innovators and entrepreneurs, powering solutions to global challenges.
The registration for in-person or virtual attendance at INNOVEIT Stockholm is now open.
ENDS
Notes for the Editor
European Institute of Innovation and Technology (EIT)
The EIT is an EU body and an integral part of Horizon Europe, the EU Framework Programme for Research and Innovation. The Institute supports dynamic pan-European partnerships, EIT Knowledge and Innovation Communities, among leading companies, research labs, and universities. The EIT is Europe’s largest innovation ecosystem bringing together close to 3 000 partners from top business, research and education organisations across Europe in 200+ hubs. More than 3 800 students have graduated from EIT labelled master and doctoral programmes and over 100 000 have participated in EIT Community entrepreneurial trainings.
EIT HEI Initiative: Innovation Capacity Building for Higher Education
The EIT HEI Initiative: Innovation Capacity Building for Higher Education is a joint EIT Community programme led by EIT RawMaterials − one of the EIT’s Knowledge and Innovation Communities. The initiative aims to support higher education institutions with expertise and coaching, access to the EIT innovation ecosystem, and funding, enabling them to develop innovation action plans contextualised to the needs of individual higher education institutions. In July 2021, 23 projects started their activities after the EIT HEI Initiative Pilot Call. By 2027, the EIT HEI Initiative aims to support 550 higher education institutions boosting European innovation in higher education and driving the twin transition towards a more sustainable, digital and competitive Europe.
EIT RawMaterials
The objective of EIT RawMaterials is to secure a sustainable raw materials supply by driving innovation, education, and entrepreneurship across European industrial ecosystems. EIT RawMaterials provides a collaborative environment for disruptive and breakthrough innovations by connecting business with academia, research, and investment. It also invests in future generations of innovators for the raw materials sector, through initiatives ranging from the education of school students to higher qualifications for industry professionals.
The company is committed to supporting Europe’s transition towards a circular, green, and digital economy whilst strengthening its global competitiveness and securing employment. On this foundation, EIT RawMaterials has been mandated by the European Commission to lead and manage the European Raw Materials Alliance (ERMA).
EIT RawMaterials – developing raw materials into a major strength for Europe. Connecting Matters!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005543/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom